Dongkook Pharmaceutical Co Ltd (086450)

KOSDAQ
Currency in KRW
15,650
-350(-2.19%)
Closed

086450 Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa482,280.35559,103.46594,193.12661,647.49730,993.6
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+20.33%+15.93%+6.28%+11.35%+10.48%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa191,807.55221,983.25244,271.95281,999.19320,442.83
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa290,472.8337,120.21349,921.17379,648.3410,550.77
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+22.22%+16.06%+3.8%+8.5%+8.14%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa60.23%60.3%58.89%57.38%56.16%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa221,754.46254,517.91286,701.87306,107.21343,677.47
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa+21.48%+14.77%+12.65%+6.77%+12.27%
aa.aaaa.aaaa.aaaa.aaaa.aa19,890.118,858.5124,691.4921,817.9625,455.62
aa.aaaa.aaaa.aaaa.aaaa.aa198,004.59231,529.18256,857.11278,306.79311,205.54
aa.aaaa.aaaa.aaaa.aaaa.aa744.73732.4887.71,350.261,277.85
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa68,718.3582,602.363,219.373,541.0866,873.3
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+24.68%+20.2%-23.47%+16.33%-9.07%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa14.25%14.77%10.64%11.11%9.15%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa1,751.7912.39-428.69-1,417.14-609.62
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+16.29%-47.91%-146.98%-230.58%+56.98%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-618.99-1,796.2-2,883.09-4,319.78-5,867.71
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa2,370.692,708.592,454.42,902.645,258.09
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa2,781.7-5,362.274,620.391,226.42-365.28
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa73,251.7578,152.4267,41173,350.3765,898.41
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa-341.3-2.32966.3618.82752.89
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa75,628.9980,030.7769,753.6468,632.560,837.64
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+19.84%+5.82%-12.84%-1.61%-11.36%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa15.68%14.31%11.74%10.37%8.32%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa16,578.8722,150.2816,837.1913,875.7311,966.26
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa59,050.1257,880.4952,916.4554,756.7748,871.39
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa-2,737.87-1,955.47-2,571.23-1,860.84-1,696.18
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa56,312.2455,925.0250,345.2252,895.9347,175.2
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+19.94%-0.69%-9.98%+5.07%-10.82%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa11.68%10%8.47%7.99%6.45%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa56,312.2455,925.0250,345.2252,895.9347,175.2
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa1,281.331,272.521,145.561,203.461,073.13
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+19.94%-0.69%-9.98%+5.05%-10.83%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa1,2591,2511,1261,1831,055
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+18.8%-0.64%-9.99%+5.06%-10.82%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa43.9543.9543.9543.9543.96
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa44.7244.7244.7244.7244.73
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa----180
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa82,334.1897,714.1680,577.3192,727.8787,970.9
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+28.23%+18.68%-17.54%+15.08%-5.13%
EBITDA Margin %
aa.aa